See more : Pricol Limited (PRICOLLTD.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Neurogene Inc. (NGNE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Neurogene Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Pioneer Merger Corp. (PACX) Income Statement Analysis – Financial Results
- Oscotec Inc. (039200.KQ) Income Statement Analysis – Financial Results
- GT Legend Automotive Holdings Inc. (GTLA) Income Statement Analysis – Financial Results
- DL Construction Co., Ltd. (001880.KS) Income Statement Analysis – Financial Results
- Kyoritsu Printing Co., Ltd. (7838.T) Income Statement Analysis – Financial Results
Neurogene Inc. (NGNE)
About Neurogene Inc.
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.26M | 3.20M | 2.28M | 1.82M | 340.00K | 0.00 | 0.00 | 0.00 | 0.00 | 135.95K | 59.57K | 130.78K | 125.60K |
| Gross Profit | -3.26M | -3.20M | -2.28M | -1.82M | -340.00K | 25.00M | 0.00 | 0.00 | 0.00 | -135.95K | -59.57K | -130.78K | -125.60K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 44.39M | 47.51M | 42.26M | 24.34M | 6.32M | 32.79M | 36.27M | 28.38M | 15.80M | 17.94M | 7.54M | 5.91M | 8.58M |
| General & Administrative | 11.19M | 9.01M | 8.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.19M | 9.01M | 8.27M | 15.39M | 17.79M | 15.74M | 14.85M | 9.26M | 5.54M | 4.30M | 1.78M | 1.64M | 1.73M |
| Other Expenses | -28.00K | -7.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 55.58M | 56.52M | 50.53M | 39.73M | 24.10M | 48.52M | 51.12M | 37.65M | 21.34M | 22.24M | 9.32M | 7.55M | 10.30M |
| Cost & Expenses | 55.58M | 56.52M | 50.53M | 41.55M | 24.44M | 48.52M | 51.12M | 37.65M | 21.34M | 22.38M | 9.38M | 7.68M | 10.43M |
| Interest Income | 2.95M | 1.34M | 17.00K | 490.00K | 1.54M | 1.56M | 998.00K | 619.00K | 0.00 | 0.00 | 26.32K | 10.80K | 19.75K |
| Interest Expense | 12.00K | 2.00K | 0.00 | 0.00 | 1.00K | 4.00K | 4.00K | 1.00K | 99.00K | 2.25M | 42.92K | 0.00 | 0.00 |
| Depreciation & Amortization | 3.30M | 3.20M | 2.28M | 1.82M | 340.00K | 0.00 | 1.00 | 1.00 | -421.00K | 135.95K | 59.57K | 130.78K | 125.60K |
| EBITDA | -52.29M | -51.99M | -49.59M | -31.46M | -69.10M | -31.58M | -50.18M | -37.00M | -21.76M | -21.65M | -8.63M | -7.54M | -10.54M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -94.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -55.58M | -56.52M | -50.53M | -41.55M | -24.44M | -23.52M | -51.12M | -37.65M | -21.34M | -22.38M | -9.38M | -7.68M | -10.43M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -94.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 19.27M | 1.33M | 17.00K | 8.28M | -45.00M | -8.06M | 936.00K | 643.00K | -520.00K | -1.65M | 641.24K | 9.11K | -232.21K |
| Income Before Tax | -36.32M | -55.19M | -50.52M | -33.28M | -69.44M | -31.59M | -50.18M | -37.00M | -21.86M | -24.03M | -8.73M | -7.67M | -10.66M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -126.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -5.00K | 17.00K | -1.00 | 168.14K | 0.00 | -1.00 | -1.00 | 0.00 | -222.00 | -5.04K | 42.29K | -154.47K |
| Net Income | -36.32M | -55.19M | -50.52M | -33.28M | -69.44M | -31.59M | -50.18M | -37.00M | -21.86M | -23.82M | -8.73M | -7.71M | -10.51M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -126.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.83 | -4.30 | -0.92 | -0.64 | -2.57 | -1.34 | -2.14 | -1.96 | -1.73 | -2.75 | -0.87 | -0.77 | -1.05 |
| EPS Diluted | -2.83 | -4.30 | -0.92 | -0.64 | -2.57 | -1.34 | -2.14 | -1.96 | -1.73 | -2.75 | -0.87 | -0.77 | -1.05 |
| Weighted Avg Shares Out | 12.82M | 12.82M | 55.04M | 51.83M | 27.03M | 23.52M | 23.45M | 18.89M | 12.64M | 8.67M | 10.05M | 10.05M | 10.05M |
| Weighted Avg Shares Out (Dil) | 12.82M | 12.82M | 55.04M | 51.83M | 27.03M | 23.52M | 23.45M | 18.89M | 12.64M | 8.67M | 10.05M | 10.05M | 10.05M |
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (NASDAQ: NGNE) (“Neurogene” or “the Company”), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the appointment of Julie Jordan, M.D., as Chief Medical Officer....
Neurogene Announces Business Update and 2024 Outlook
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (NASDAQ: NGNE) (“Neurogene” or “the Company”), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, announced today a business update and provided its outlook for 2024. Key...
Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (NASDAQ: NGNE) (“Neurogene”), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the closing of its merger with Neoleukin Therapeutics, Inc. (“Neoleukin”). Neurogene shares are...
Source: https://incomestatements.info
Category: Stock Reports